NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 115 filers reported holding NURIX THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,299,100 | -49.4% | 130,040 | -55.0% | 0.00% | -50.0% |
| Q1 2023 | $2,564,899 | +82161.0% | 288,840 | +1.5% | 0.01% | -38.5% |
| Q4 2022 | $3,118 | -99.9% | 284,701 | +19.5% | 0.01% | 0.0% |
| Q3 2022 | $3,101,000 | -61.8% | 238,204 | -61.1% | 0.01% | -7.1% |
| Q2 2022 | $8,124,000 | +90.5% | 612,002 | +100.4% | 0.01% | +7.7% |
| Q1 2022 | $4,265,000 | -17.2% | 305,340 | +72.8% | 0.01% | 0.0% |
| Q4 2021 | $5,152,000 | +72.0% | 176,666 | +83.4% | 0.01% | +85.7% |
| Q3 2021 | $2,995,000 | +281.0% | 96,350 | +228.4% | 0.01% | +250.0% |
| Q2 2021 | $786,000 | -80.4% | 29,340 | -77.3% | 0.00% | -77.8% |
| Q1 2021 | $4,008,000 | – | 129,240 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |